2.69
-0.035(-1.29%)
Currency In USD
| Previous Close | 2.72 |
| Open | 2.72 |
| Day High | 2.76 |
| Day Low | 2.63 |
| 52-Week High | 117.2 |
| 52-Week Low | 2.55 |
| Volume | 39,572 |
| Average Volume | 431,860 |
| Market Cap | 4.75M |
| PE | -0.14 |
| EPS | -19.74 |
| Moving Average 50 Days | 4.12 |
| Moving Average 200 Days | 19.58 |
| Change | -0.04 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $26.48 as of February 05, 2025 at a share price of $2.685. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $189.08 as of February 05, 2025 at a share price of $2.685.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025
GlobeNewswire Inc.
Jan 17, 2025 1:00 PM GMT
Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire Inc.
Jan 15, 2025 1:30 PM GMT
Live video webcast on Wednesday, January 22nd at 4:00 PM ET THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technol
Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting
GlobeNewswire Inc.
Jan 13, 2025 1:30 PM GMT
THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous sy